# Finerenone for Regression of Albuminuria in Type 2 Diabetes With Chronic Kidney Disease

> **NCT07667517** · PHASE4 · NOT_YET_RECRUITING · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 148 (estimated)

## Conditions studied

- Albuminuria
- Type 2 Diabetes Mellitus (T2DM)
- Chronic Kidney Diseases

## Interventions

- **DRUG:** Finerenone (BAY 94-8862)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07667517
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2027-10-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 148 (ESTIMATED)
- **Last updated:** 2026-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07667517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07667517, "Finerenone for Regression of Albuminuria in Type 2 Diabetes With Chronic Kidney Disease". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07667517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*